Investigational and not approved by the FDA. This page is educational information only. It is not medical advice and not a recommendation to use anything.

IndexedBuilt automatically from public databases on 2026-09-30. Not yet hand-reviewed by PLOBT.How this works →

Aviptadil

Investigational

Synthetic vasoactive intestinal peptide

Also known as: VIP, vasoactive intestinal peptide, Zyesami, invicorp, Vip human vip, Vasoactive intestinal octacosapeptide, RLF-100, aviptadilum, Samiairtm, Samiviptm

Evidence score

58/ 100

Moderate evidence

A real evidence base, with gaps

Regulatory standing. In clinical trials, not yet approved
Limited human data. Some human data exists, not conclusive
Registered human trials. 9 registered studies on ClinicalTrials.gov, most advanced Phase 3
1 cited source. Includes primary / regulatory sources

Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.

What it is

Aviptadil is a synthetic form of vasoactive intestinal peptide (VIP), a 28 amino acid hormone the body makes naturally in the gut, lungs, and nervous system. VIP binds to VPAC receptors and is thought to relax smooth muscle, widen blood vessels, and dampen inflammation, including in lung tissue. It has been studied under the name Zyesami, mainly as an inhaled or intravenous treatment for lung injury.

What the evidence shows

Automatic summaryLimited human data

Aviptadil is investigational and not FDA-approved. About nine registered human trials exist, reaching Phase 3 in respiratory failure linked to COVID-19, but the results have been mixed and have not established a clear benefit.

Key facts

Molecular formula

C147H237N43O43S

Molecular weight

3326.8 g/mol

Registered human trials

Live from ClinicalTrials.gov, refreshed daily.

9registered studies

Phase 3most advanced phase

4completed (sample)

0recruiting (sample)

ZYESAMI (Aviptadil) Intermediate Population Expanded Access Protocol (SAMICARE)

No Longer AvailableNCT04453839

ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19

Phase 3CompletedNCT04843761

A Clinical Study Evaluating Inhaled Aviptadil on COVID-19

Phase 2CompletedNCT04844580

Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure

Phase 3CompletedNCT04311697

Published literature

Live from Europe PMC. This is how much has been published, not how much is proven in humans.

54papers referencing Aviptadil

Inhalation of vasoactive intestinal peptide in pulmonary hypertension.

Eur Respir J2008

Novel Targets of Drug Treatment for Pulmonary Hypertension.

Am J Cardiovasc Drugs2015

The Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure: Results of a 60-Day Randomized Controlled Trial.

Crit Care Med2022

Erectile dysfunction: a global review of intracavernosal injectables.

World J Urol2019

Sources

Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.